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The clinical diagnosis of vascular dementia (VaD) is based on imaging criteria, and specific
biochemical markers are not available. Here, we investigated the potential of cerebrospinal
fluid (CSF) lipocalin 2 (LCN2), a secreted glycoprotein that has been suggested as mediating
neuronal damage in vascular brain injuries. The study included four independent cohorts with
a total n= 472 samples. LCN2 was significantly elevated in VaD compared to controls,
Alzheimer’s disease (AD), other neurodegenerative dementias, and cognitively unimpaired
patients with cerebrovascular disease. LCN2 discriminated VaD from AD without coexisting
VaD with high accuracy. The main findings were consistent over all cohorts. Neuropathology
disclosed a high percentage of macrophages linked to subacute infarcts, reactive astrocytes,
and damaged blood vessels in multi-infarct dementia when compared to AD. We conclude
that CSF LCN2 is a promising candidate biochemical marker in the differential diagnosis of
VaD and neurodegenerative dementias.
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Vascular dementia (VaD) is considered one of the mostcommon causes of dementia after Alzheimer’s disease(AD)1. Identifying VaD patients for epidemiological or
clinical research and clinical trials as well as monitoring of
therapeutic interventions in VaD trials is challenging. Despite the
importance of the disease, diagnosis has been hampered by the
lack of well-defined standardized criteria. Commonly used cri-
teria2 have suboptimal diagnostic accuracy3,4. Unified neuro-
pathological criteria have not been available5 in the past and
recently published guidelines6 have not yet been widely adopted.
A research framework for AD proposed in 20187 includes cere-
brospinal fluid (CSF) and imaging markers of tau and amyloid-
pathology. Recent efforts to standardize and harmonize diagnosis
in VaD have led to a consensus study on vascular cognitive
impairment (VCI)8 and the suggestion of imaging and neu-
ropsychological criteria. However, no specific fluid marker for
VaD has been established in the clinical routine to date. Imaging
markers related to vascular brain injury (VBI), e.g., white matter
hyperintensities (WMH) on magnetic resonance imaging (MRI)
are accepted markers for VaD9,10 and provide valuable infor-
mation about cerebrovascular pathology in morphological terms,
but they are not pathognomonic10. The nature of their association
with dementia has not been fully clarified and further research is
still needed11–13. Mixed forms of dementia (such as VaD plus
AD) are frequent and differentiation from pure forms of AD and
VaD is not always possible14. In addition, WMH are frequent in
patients with AD15 and might be caused by neurodegeneration16.
In summary, new biomarkers are needed to improve diagnosis, to
uncover the pathophysiology, and to monitor clinical trials17–20.
Lipocalin 2 (LCN2) is a secreted glycoprotein involved in
innate immunity and highly expressed in the central nervous
system in response to injury and inflammatory stimuli21. It
has been discussed as a potential marker for AD22. Studies in
humans have shown slightly elevated levels of LCN2 in plasma
of patients with mild cognitive impairment (MCI)23 and in CSF
of patients with multiple sclerosis24. LCN2 has also been dis-
cussed as an attractive blood-based biomarker of inflammation,
ischemia25, and, in particular kidney injury26,27. Experimental
models of VaD have shown that LCN2 mediates hippocampal
damage and that LCN2 deficiency is associated with less white
matter damage and cognitive decline28 but LCN2 has not been
clinically evaluated in the context of differential diagnosis of VaD.
The primary aim of the study was to investigate the potential of
LCN2 as a biomarker for VaD. Therefore, we compared CSF
LCN2 levels in different forms of dementia, VBI, and controls.
Regarding the importance and known difficulties in the clinical
differentiation between AD and VaD, we validated our results
using independent cohorts. In addition, neuropathological ana-
lyses were performed to provide information on the location of
LCN2 in brain tissue of patients with chronic multi-infarct
dementia (MID), and those with AD.
Our results show that CSF LCN2 is elevated in patients with
VaD compared to controls, cognitively unimpaired patients with
VBI, and other forms of dementia. The high diagnostic accuracy
highlights its potential as a biomarker for VaD in the differential
diagnosis of dementia. Our neuropathological investigations
display different expression of LCN2 in brains of patients with
VaD and AD.
Results
Group descriptions. Data on age, sex and CSF biomarkers in all
cohorts are presented in Table 1. In general, more samples from
female patients were analysed (254 female, 218 male). VaD patients
were older than those from other diagnostic groups. Patients with
VaD, Lewy body dementias (LBD), and fronto-temporal dementia
(FTD) showed similar profiles of established CSF biomarkers (t-tau,
p-tau and amyloid beta 42). Patients with sporadic Creutzfeldt-
Jakob disease (CJD) showed highly elevated CSF t-tau. Patients with
AD and mixed dementia (MD, AD plus VaD) showed a typical
signature of AD-pathology associated biomarkers7.
LCN2 in the differential diagnosis of dementia. Cohort 1
included VaD (n= 27), MD (n= 31), AD (n= 47), LBD
Table 1 Demographics and biomarkers data from the different cohorts.
n Age Sex (f/m) t-Tau (pg/mL) p-Tau (pg/mL) Amyloid β42 (pg/mL) Lipocalin 2 (pg/mL)
Cohort 1
ND 73 67 ± 10 40/33 232 ± 207 40 ± 11 719 ± 351 771 ± 347
AD 47 67 ± 10 26/21 591 ± 435 90 ± 51 449 ± 207 691 ± 247
VaD 27 72 ± 8 17/10 386 ± 445 44 ± 15 779 ± 348 2233 ± 1326
MD 31 74 ± 10 25/6 444 ± 272 76 ± 54 437 ± 206 1565 ± 833
LBD 36 69 ± 11 18/18 385 ± 301 56 ± 42 513 ± 292 917 ± 398
FTD 21 65 ± 12 8/13 373 ± 370 57 ± 21 665 ± 251 762 ± 331
CJD 54 68 ± 10 27/27 5936 ± 5914 61 ± 18 635 ± 324 1037 ± 661
SVDND 20 63 ± 14 9/11 181 ± 135 34 ± 16 787 ± 229 753 ± 300
VCIND 7 66 ± 9 2/5 177 ± 59 48 ± 12 1114 ± 220 946 ± 366
Cohort 2
ND 24 64 ± 8 12/12 168 ± 74 35 ± 14 913 ± 409 713 ± 232
AD 15 68 ± 6 6/9 602 ± 336 71 ± 27 417 ± 95 660 ± 182
VaD 10 69 ± 10 3/7 330 ± 236 38 ± 13 768 ± 188 1440 ± 979
Cohort 3
ND 15 67 ± 13 7/8 193 ± 57 33 ± 9 684 ± 123 753 ± 386
AD 27 72 ± 6 16/11 647 ± 307 88 ± 29 435 ± 81 709 ± 236
VaD 16 74 ± 6 10/6 402 ± 300 55 ± 23 501 ± 134 1381 ± 953
Cohort 4
AD 28 72 ± 10 21/7 595 ± 234 86 ± 25 634 ± 228 634 ± 198
SVDND 3 71 ± 8 1/2 135 ± 37 27 ± 9 953 ± 55 613 ± 258
VCIND 8 67 ± 5 3/5 174 ± 45 38 ± 12 869 ± 328 845 ± 277
VaD 10 76 ± 6 3/7 248 ± 66 43 ± 11 932 ± 221 1131 ± 481
Number of cases (n), age (mean ± standard deviation), sex (female/male), CSF biomarkers total-Tau, p-Tau and amyloid beta 42 and CSF LCN2 (mean ± standard deviation in pg/mL) are indicated.
ND non-primarily neurodegenerative and non-ischemic neuropsychiatric diseases, AD Alzheimer’s disease, VaD vascular dementia, MD mixed dementia, LBD Lewy body dementia, FTD frontotemporal
dementia, CJD sporadic Creutzfeldt-Jakob disease, SVDND small vessel disease no dementia, VCIND vascular cognitive impairment no dementia.
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(n= 36), FTD (n= 21), CJD (n= 54), as well as non-primarily
neurodegenerative and non-ischemic neuropsychiatric diseases
(ND, n= 73). In a multi-comparative analysis corrected for
covariates, LCN2 concentrations were significantly increased in
VaD and MD compared to ND (p < 0.001, Tukey contrast for
multiple comparisons of means) and other diagnostic groups
(Table 1, Fig. 1a). No significant difference between VaD and MD
could be observed. The diagnostic accuracy of LCN2 in the dif-
ferentiation from ND is indicated by areas under the curve
(AUC) and 95% confidence intervals (95% CI) in Fig. 1b, c. LCN2
concentrations discriminated ND from VaD (AUC= 0.88, 95%
CI: 0.80–0.96, p < 0.001) and MD (AUC= 0.85, 95% CI:
0.77–0.93, p < 0.001) with high accuracy. LCN2 was able to dis-
criminate AD from VaD (AUC= 0.9, 95% CI: 0.82–0.98, p <
0.001, z test with H0: AUC= 0.5 in all cases) with a sensitivity of
82% and a specificity of 87%, as well as ND from VaD with a
sensitivity of 78% and a specificity of 82%. In contrast, LCN2
levels showed no diagnostic value in distinguishing AD, LBD,
FTD, and CJD from ND (p > 0.05, z test with H0: AUC= 0.5).
LCN2 discriminates VaD from AD in validation cohorts. To
validate the presence of elevated LCN2 concentrations in VaD,
two independent cohorts (cohort 2 and 3) including ND, AD, and
VaD cases were analysed with linear regression models adjusted
for covariates and posterior multiple comparisons of means were
performed with Tukey contrasts. In cohort 2, LCN2 was sig-
nificantly increased in VaD (n= 10) compared to ND (n= 24,
p < 0.01) and AD (n= 15, p < 0.01). It discriminated VaD from
AD with an AUC of 0.88 (Fig. 2a). In cohort 3, LCN2 was sig-
nificantly increased in VaD (n= 16) compared to ND (n= 15,
p < 0.05) and AD (n= 27, p < 0.001). It discriminated VaD from
AD with an AUC of 0.83 (Fig. 2b). AUCs derived from ND vs.
VaD and AD vs. VaD comparisons were not significantly dif-
ferent (z test) between the cohorts (Supplementary Table 1). In
cohort 4, LCN2 was significantly increased in VaD (n= 10)
compared to AD (n= 28, p < 0.05, Tukey contrast) but no control
group (ND) was available (Fig. 3b). In a separate statistical model
including Mini Mental Status Examination (MMSE) score in the
group of covariates, VaD groups showed significantly higher
LCN2 levels than AD groups in all four cohorts, indicating that
dementia stage does not significantly alter the results (Supple-
mentary Table 2).
VaD types, dementia stage, WMH, and albumin ratio.
Regarding different types of VaD, LCN2 levels seemed to be
similar in subcortical ischemic vascular dementia (SID) and
multi-infarct (cortical) dementia (MID) while being lower in
post-(single)stroke dementia (PSD) (Table 2). We could not
investigate this observation further because case numbers were
too low after building the diagnostic subgroups. Especially for
PSD, only few cases were identified.
To assess the association between LCN2 and cognitive
impairment in patients with cerebrovascular pathology, LCN2
concentrations were quantified in two cohorts that included
cerebral small vessel disease but no dementia (SVDND), vascular












































AUC ± SE (95%) CI p-value
AD vs VaD 0.9 ± 0.04 (0.82–0.98) <0.001
ND vs AD 0.53 ± 0.05 (0.43–0.64) 0.52
ND vs VaD 0.88 ± 0.04 (0.80–0.96) <0.001
ND vs MD 0.85 ± 0.04 (0.77–0.93) <0.001
ND vs LBD 0.62 ± 0.06 (0.51–0.74) 0.06
ND vs FTD 0.50 ± 0.07 (0.36–0.65) 0.99
ND vs CJD 0.59 ± 0.05 (0.49–0.70) 0.07
Fig. 1 CSF LCN2 in the differential diagnosis of dementia (cohort 1). a LCN2 in non-primarily neurodegenerative and non-ischemic neuropsychiatric
diseases (ND, n= 73), Alzheimer’s disease (AD, n= 47), vascular dementia (VaD, n= 27), mixed Alzheimer’s and vascular dementia (MD, n= 31), Lewy
body dementias (LBD, n= 36), frontotemporal dementia (FTD, n= 21), and sporadic Creutzfeldt-Jakob disease (CJD, n= 54). Results are shown as mean
± SD for each condition. b Area under the curve (AUC) derived from receiver operating characteristic (ROC) curves, Standard Error (SE), 95% Confidence
interval (95% CI) for LCN2 in the comparative analyses. c ROC curves of differentiating ND and VaD as well as AD and VaD. Differences between groups
were analysed with Tukey contrasts using linear regression models controlled for age and sex. *p < 0.05, **p < 0.01, ***p < 0.001.
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1 and 4). AD cases were included in the multi-comparative analysis
(linear regression adjusted for covariates) in order to compare
baseline LCN2 in non-vascular pathology. In cohort 1, LCN2
concentrations in VaD (n= 27) were significantly different from
AD (n= 47), SVDND (n= 20), and VCIND (n= 7) (p < 0.01,
Tukey contrast for multiple comparisons of means) (Fig. 3a).
In cohort 4, VaD (n= 10) displayed higher LCN2 concentrations
than AD (n= 28), SVDND (n= 3), and VCIND (n= 8), although
significant differences were only detected between AD and VaD
groups (p < 0.05) (Supplementary Table 1, Fig. 3b). Additional
association analyses of LCN2 and MMSE scores including all
groups with cerebrovascular disease (SVDND, VCIND, and VaD)
showed highly significant negative correlations in cohort 1 (cc=
−0.55, p < 0.0001, Fig. 3c, Spearman correlation test) and cohort 4
(cc=−0.56, p= 0.008, Fig. 3d, Spearman correlation test). In AD
groups, we observed no significant correlation (cohort 1: cc= 0.16,
cohort 4: cc=−0.06, Supplementary Fig. 1a, Supplementary
Fig. 1b).
We investigated the association of white matter changes and
LCN2 in patients with cerebrovascular disease (SVDND, VCIND,
and VaD) in cohorts 1 and 4 excluding patients with radiological
evidence for cortical infarctions (Fig. 3e, f). LCN2 levels showed a
significant positive correlation with the Age-Related White Matter
Changes (ARWMC) scale in cohort 1 (cc= 0.33, p= 0.037,
Spearman correlation test) and a non-significant positive correla-
tion with the Fazekas scale in cohort 4 (cc= 0.38, p= 0.15,
Spearman correlation test).
The CSF/serum albumin ratio (QAlb) is a well-known marker
of blood-brain-barrier (BBB) function and was measured in the
continuum of vascular pathology in cohort 1 and 4. It was
significantly elevated in VaD compared to SVDND (p < 0.05 One-
way ANOVA Bonferroni’s post hoc) (Supplementary Fig. 2a),
presenting a strong positive correlation with LCN2 in SVDND
and VaD and non-significant positive correlation in VCIND
(Supplementary Fig. 2b).
Association with demographics and other biomarkers.
LCN2 showed a weak non-significant positive correlation with
age in all cohorts when all diagnostic groups were analysed
(Supplementary Table 3). Yet, all group comparisons were
adjusted for age and sex (Fig. 1, Fig. 2, Supplementary Fig. 2,
Supplementary Table 2) to exclude that these factors behave as
relevant confounders. Associations between LCN2 concentra-
tions and demographic parameters as well as CSF total-Tau, p-
Tau, and amyloid beta 42 were analysed in all VaD (n= 62) and
AD (n= 117) cases. In VaD, LCN2 showed a significant positive
correlation with total-Tau (cc= 0.34, p= 0.006, Spearman
correlation test) but not with other studied parameters
(Table 3). In contrast, no significance was observed in AD (cc=
0.05, p= 0.57, Spearman correlation test). Since LCN2 has been
discussed as a blood-based marker for kidney injury, we ret-
rospectively reviewed medical files of all AD and VBI cases to
identify those with kidney injury and included this condition in
the regression model as an additional covariate. It was not a
significant variable in the model (p= 0.711 for the significance
of the β estimate) and differences of LCN2 levels between
groups were not affected. Therefore, we did not consider the
presence of kidney injury to be a significant confounder.
LCN2 expression in the brain of AD and VaD. We included
controls (n= 11, mean age ± SD, 56.3 ± 8.4), “pure” AD (co-mor-
bidities were restricted to minimal small vessel disease, n= 10,
mean age ± SD: 76.6 ± 6.0), and MID cases (n= 11, mean age ± SD:
72.5 ± 11.4) for neuropathological studies. In control brains, we
detected LCN2 immunoreactivity in capillaries and resting micro-
glia (Fig. 4a, upper- left). In AD cases (stages V and VI), LCN2
immunoreactivity was preserved in capillaries but increased in a
subpopulation of astrocytes localized around β-amyloid plaques or
layered in the cerebral cortex, and in reactive microglia (Fig. 4a,
upper-right). Lesions at different evolution states were observed in
all cases with MID. These lesions included rare acute infarcts in
which acute necrosis was the predominant alteration, subacute
infarcts with abundant macrophages and variable peripheral reac-
tive astrocytes, and old, often cystic, infarcts with a necrotic center
surrounded by a scar of astrocytes (chronic reactive astrocytosis).
Massive LCN2 immunoreactivity was observed in subacute infarct
areas (MID-SAI area) and in macrophages (Fig. 4a, bottom- left
insert). Additional LCN2 immunoreactivity occurred in reactive
astrocytes as seen in small numbers in the peripheral region of
subacute infarcts (Fig. 4a, bottom left) and in the astrocytic scar
area surrounding a cystic area in large infarcts or replacing
deceased neurons in small infarcts (MID-AS area) (Fig. 4a bot-
tom right). Total LNC2 staining was analysed by Kruskal-
































ND vs VaD AD vs VaD
AUC 0.81 0.88
Standard error 0.08 0.07
95% CI 0.64–0.97 0.75–1
ND vs VaD AD vs VaD
AUC 0.77 0.83
Standard error 0.08 0.06
95% CI 0.60–0.93 0.70–0.95
a b
Fig. 2 Diagnostic accuracy of CSF LCN2 in the discrimination of VaD and AD (cohorts 2 and 3). a Cohort 2: LCN2 concentrations in non-primarily
neurodegenerative and non-ischemic neuropsychiatric diseases (ND, n= 24), Alzheimer’s disease (AD, n= 15), and vascular dementia (VaD, n= 10).
Area under the curve (AUC) derived from receiver operating characteristic (ROC) curves, Standard Error, and 95% CI in the comparative analysis of VaD
versus ND and AD. b Cohort 3: LCN2 concentrations in ND (n= 15), AD (n= 27), and VaD (n= 16). AUC derived from ROC curves, Standard Error, 95%
CI in the comparative analysis of VaD versus ND and AD. Differences between groups were analysed with Tukey contrasts using linear regression models
controlled for age and sex. *p < 0.05, **p < 0.01, ***p < 0.001.
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increased immunoreactivity in MID in comparison with AD
(p < 0.05) and controls (p < 0.001, Fig. 4b).
Double-labeling immunofluorescence to GFAP and
LCN2 showed that about 58% of astrocytes in AD, 12% of
astrocytes in the peripheral region of subacute infarcts, and 32%
of astrocytes at the periphery of chronic infarcts expressed
LCN2 (Fig. 5a, c, e). In contrast, double-labeling immuno-
fluorescence disclosed that about 75% of Iba1-positive cells in
subacute infarcts expressed LCN2. About the same percentage
or even more LCN2-immunoreactive cells were macrophages
(Fig. 5b, d, e).
IgG and Fibrinogen immunoreactivity was detected in the
perivascular space in AD and VaD, but not in controls
(Supplementary Fig. 3), suggesting BBB impairment in both
diseases and the absence of differential contribution of BBB
alteration to the CSF concentrations of LCN2 in AD and VaD.
Discussion
Imaging markers like N-acetyl aspartate (NAA) in proton mag-
netic resonance spectroscopy for Binswanger’s disease29 and
candidate CSF markers like Qalb30,31, neurofilament light32, and
matrix metalloproteinases33 for VaD have been suggested in
recent years. These markers have shown uncertain or at best
moderate diagnostic accuracy34,35.
The results from cohort 1 show that LCN2 levels might allow
accurate differentiation between VaD and neurological controls
as well as all other investigated causes of dementia. The broad
spectrum of different dementia types analysed underlines the
potential clinical value of the marker. However, cases numbers
were rather low. Therefore, we investigated two independent
cohorts (cohort 2 and 3) and were able to validate our findings
through multi-national European cooperation. The results
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Fig. 3 Associations of CSF LCN2, cognitive status, and white matter changes (cohorts 1 and 4). a Cohort 1: LCN2 levels in Alzheimer’s disease (AD,
n= 47), small vessel disease no dementia (SVDND, n= 20), vascular cognitive impairment no dementia (VCIND, n= 7), and vascular dementia (VaD,
n= 27). b Cohort 4: LCN2 levels in AD (n= 28), SVDND (n= 3), VCIND (n= 8), and VaD (n= 10). Differences between groups were analysed with
Tukey contrasts using linear regression models controlled for age and sex. *p < 0.05, **p < 0.01, ***p < 0.001. a, b Mean ± SD is represented in the graphs.
c, d Correlation analysis of LCN2 and Mini Mental Status Examination (MMSE) scores in SVDND, VCIND, and VaD in cohort 1 (n= 48) (c) and cohort
4 (n= 21) (d). Spearman correlation test, correlation coefficients (cc) and associated two-tailed p values. e CSF LCN2 and age-related white matter
changes (ARWMC) in SVDND, VCIND, and VaD in cohort 1 (n= 50). Spearman correlation test, correlation coefficients (cc), and associated two-tailed
p values. f LCN2 and Fazekas scale in SVDND, VCIND, and VaD in cohort 4 (n= 21). Spearman correlation test, correlation coefficients (cc), and
associated two-tailed p values.
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Clinical and MRI data from cohort 1 and 4 suggest that higher
LCN2 levels are associated with the degree of cognitive impair-
ment in VBI, but not in AD. Regarding the different types of
VaD, LCN2 is possibly lower in patients with PSD, but low case
numbers precluded validating this observation statistically. Only
in cohort 1, the correlation of high LCN2 levels and WMH load
showed (borderline) significance. All this may indicate that LCN2
is closely associated with clinical disease stage in VaD rather than
with common imaging markers. Further investigations and dee-
per analyses of MRI markers (atrophy, infarct volume, WMH
volume, etc.) will need to explore these assumptions and the
presence of VaD patients with unaltered or only slightly elevated
CSF LCN2 levels in all cohorts. Here, we focused on the asso-
ciation between LCN2 levels and clinical diagnosis.
A previous study showed elevation of plasma LCN2 in patients
with amnestic MCI but, in line with our results, not in demented
patients with AD23. Inflammatory processes in early AD stages
were suggested as a possible cause but concomitant vascular
pathology was not excluded and diagnostic accuracy was not
evaluated. Another study reported an elevation of CSF LCN2 and
a positive correlation with neurofilament light in patients
with progressive multiple sclerosis, but the increase was moderate
and the authors stated that LCN2 was likely not a suitable bio-
marker for the clinical diagnosis of this condition24.
Considering this, LCN2 may be a valuable biomarker for
VaD in the context of differential diagnosis. Such a marker has
long been pursued17,18,34. Besides new imaging markers that
display functional consequences of vascular lesions29,36, fluid
markers like LCN2 are candidates to contribute to a biomarker-
based definition of VaD as has recently been proposed for AD7.
LCN2 is synthesized and secreted as an inducible factor from
activated microglia, reactive astrocytes, neurons, and endothe-
lial cells in response to inflammatory, infectious, and injurious
insults, in all of which it plays varied functions37. Several lines
of evidence implicate LCN2 in the progression of cerebral
infarcts38.
Because the pathophysiology of LCN2 in VaD has not yet been
resolved, caution is necessary when disclosing the molecular
causes of LCN2 alterations in biological fluids. In cohort 1 and
cohort 4, Qalb was strongly associated with LCN2 levels. Since
disturbance of the BBB is a core feature of the pathophysiology of
VaD39, elevated CSF LCN2 might be related to impaired BBB
function like it has been assumed to be the case for Qalb. How-
ever, LCN2 seems to differentiate VaD from other forms of
dementia better than what has been shown for Qalb30,31,34.
Furthermore, LCN2 also displays significant positive correlation
Table 2 Cognitive scores, white matter hyperintensities, and CSF LCN2 levels.
n MMSE
(median score, min-max)





AD 47 17 (0–27), n= 35 – 691 ± 247
VaD 27 19 (0–25), n= 21 12 (5–17), n= 23 2233 ± 1326
SID 20 19 (0–25), n= 17 12 (5–16), n= 18 2232 ± 1340
MID 5 17 (14–25), n= 3 12.5 (11–17), n= 4 2780 ± 1256
PSD 2 16, n= 1 7, n= 1 870 ± 268
VCIND 7 28 (26–29) 12 (4–18) 946 ± 366
SVDND 20 28.5 (28–30) 6 (3–19) 753 ± 300
Cohort 2
AD 15 20 (9–27), n= 14 – 660 ± 182
VaDa 10 13 (5–24), n= 9 NA 1440 ± 979
SID 1 21 NA 840
MID 6 16 (5–24) NA 1853 ± 1092
PSD 2 13 (13–13) NA 970 ± 127
Cohort 3
AD 27 21 (11–30) – 709 ± 236
VaDb 16 23.5 (12–28) NA 1381 ± 953
SID 10 21.5 (14–28) NA 1298 ± 1087
MID 2 22 (20–24) NA 2460 ± 56
Cohort 4
AD 28 23 (15–28) – 634 ± 198
VaD 10 21 (16–28) 2 (1–3) 1131 ± 481
SID 7 26 (20–28) 2 (1–3) 1147 ± 512
MID 3 18 (16–24) 1 (1–2) 1093 ± 502
VCIND 8 26 (22–28) 2 (1–2) 845 ± 277
SVDND 3 29 (28–30) 2 (2–4) 613 ± 258
a1 case data not available to determine type of VaD pathology.
b4 cases data not available to determine type of VaD pathology.
n number of cases, AD Alzheimer’s disease, VaD vascular dementia, SID subcortical ischemic vascular dementia, MID mulit-infarct cortical dementia, PSD post-(single)stroke dementia, SVDND small
vessel disease no dementia, VCIND vascular cognitive impairment no dementia.
Table 3 Correlations between CSF LCN2 levels,
demographics, and CSF biomarkers.
VaD AD
n cc p value n cc p value
Demographics
Age 63 0.11 0.37 117 0.19 0.12
Sex 63 – 0.90 117 – 0.15
CSF biomarkers
t-Tau 63 0.34 0.006 117 0.05 0.57
p-Tau 63 0.05 0.69 117 −0.12 0.20
Amyloid β42 63 −0.10 0.43 117 −0.06 0.48
Age, sex and CSF biomarkers (total-Tau, p-Tau and amyloid beta 42) in vascular dementia
(VaD) and Alzheimer’s Disease (AD) cases from all cohorts were tested for normality and
Spearman (LCN2 vs biomarkers), Pearson (LCN2 vs age) correlation tests and Mann–Whitney
test (LCN2 vs sex) were applied. Correlation coefficients (cc) and associated p values are
reported. N: number of cases.
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with CSF total-Tau in VaD but not in AD (Table 3), which might
indicate an association with the extent of neuronal damage.
Neuropathological examination of control brains indicates that
LCN2 is expressed in capillaries and microglia, but rarely in
astrocytes. In AD brains, LCN2 is expressed in reactive microglia
and reactive astrocytes. In MID brains, LCN2 is expressed in
macrophages located in subacute infarcts, in reactive astrocytes at
the periphery of subacute infarcts, and in chronic infarcts. Pre-
vious studies associated LCN2 with inflammation and cellular
damage in cerebral inflammatory diseases such as multiple
sclerosis and neuropsychiatric lupus24,40,41. LCN2 is involved in
the inflammatory activation of astrocytes42. Hypoxia induces
astrocyte-derived LCN2 in ischemic stroke43 while astrocyte-
derived LCN2 mediates hippocampal damage and cognitive def-
icits in experimental models of VaD28.
It is tempting to speculate that high LCN2 levels in the brain
may be expected in conditions with robust astrocytic gliosis such
as CJD. However, CSF LCN2 in CJD was not significantly altered
in multi-comparative analyses. Therefore, other scenarios may be
considered. VaD may present with a particular profile of reactive
astrocytes. Microglia and macrophages may be additional sources
of LCN2, and areas of subacute infarcts in MID are particularly
rich in macrophages. Unfortunately, comprehensive studies
combining clinical data, high sensitivity MRI, and CSF LCN2
levels in the progression of ischemic infarcts are not available. In
addition to alterations of the BBB, cerebrovascular diseases, and
particularly MID in the present context, show disruption of the
interface between blood vessels and Virchow-Robin spaces as well
as between Virchow-Robin spaces and brain tissue, which adjoin
to the subventricular space and the CSF. This represents another
considerable mechanism regarding abnormal protein extravasa-
tion of secreted brain proteins to the CSF.
Our study concerns an important area of research with major
socioeconomic relevance. The participating centres are specialized
institutions capable of defining patient groups with great expertise
in applying clinical and para-clinical assessments. The multi-
centre setting also allowed for demonstration of the reproduci-
bility of our findings.
The absence of a reliable gold standard for the clinical diag-
nosis of VaD is a limitation of our study. The reference standard2
and its key markers probably lack high accuracy3,11,12. We
assume that the inclusion of independent cohorts with indepen-
dent diagnostic evaluations is an appropriate way to regard this
problem and to validate the clinical reliability of the results. The
frequent occurrence of concomitant pathologies (VaD and AD) is
a problem that we tried to address by differentiating (cohort 1) or
excluding (cohorts 2, 3, 4) patients with clinical evidence of
possible MD. A biomarker for “pure” VaD may also be useful in
the differential diagnosis of MD when used in combination with
AD-related biomarkers. Since these biomarkers were part of the
reference standard for the diagnosis of AD, we could investigate
this further. In general, clinical evaluations of biomarkers of VaD
have to be interpreted with caution.
The retrospective study design and low case numbers in each
cohort have several limitations. We could not investigate relations
between kidney disease (for which LCN2 is considered to be a pro-
mising biomarker), peripheral LCN2, and CSF LCN2 further. Thus,
we cannot be sure that elevated CSF LCN2 is brain-derived and we
cannot state a specific causal relationship between LCN2 and VBI.
No sample-size calculation was performed. Different forms of
VaD8,44 were stratified but not statistically analysed. Advanced
neuropathological differentiation of cases was not available for the
clinical cohorts and it cannot be ruled out that other subtypes of
VaD (e.g. multi-infarct encephalopathy vs. sole diffuse alteration of
the white matter) may account for differences of CSF LCN2 levels
within the VaD groups. However, this did not result in low overall
diagnostic accuracy. We performed basic correlation analyses of
LCN2 and MRI markers as well as neuropathological investigation
of certain VaD subtypes, but detailed data will have to be acquired
through prospective studies to validate the findings.
Due to the case-control design, the cohorts may be biased.
Especially in cohort 1, many samples were collected in the fra-
mework of differential diagnosis of atypical or rapidly progressive
dementia, which may explain higher LCN2 levels compared to the
other cohorts. Non-identic population characteristics and pre-
analytical conditions in the study centres cannot be ruled out. By
contrast, the design and the heterogeneity of cohorts is also
a strength of the study. We could show that different LCN2 levels
in AD and VaD were consistent even though diagnostic procedures
and case selection were not performed in the same centre.
The presented clinical data indicate that CSF LCN2 is a marker
for dementia associated with VBI and that it has the potential to
become a complementary tool in the differential diagnosis of
VaD and AD. Since this is the first clinical evaluation of LCN2 in



























Fig. 4 LCN2 expression in control, AD, and MID brain tissue. a LCN2
immunohistochemistry in the cerebral cortex of control, Alzheimer’s
disease (AD), and Multi-Infarct Chronic Encephalopathy (MID) cases,
including subacute infarct areas (MID-SAI area) and astrocytic scar areas
(MID-AS area). LCN2 staining is observed in intact blood vessels in
controls, AD and MID cases (arrow-heads). Increased LCN2 expression is
observed in reactive astrocytes in AD and MID (arrows) and in monocyte/
macrophage cells of the MID-SAI area (empty arrow-heads). Paraffin
sections counterstained with hematoxylin. Bar: 25 µm; insert-bar 50 µm.
b Quantification of LCN2 positive cells area in cerebral cortex and striatum
in µm2. Significant increase of LCN2 positive cells area in MID cases with
respect to controls (***p < 0.001) and AD cases (*p < 0.05). Shown results
are means (±SD) of controls (n= 11), AD (n= 10), and MID (n= 11) cases.
In MID cases, area of subacute infraction (n= 6) and chronic infarcts (n=
11) were analysed. Results were analysed by Kruskal-Wallis followed by
Dunn's Multiple Comparison test.
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included in the clinical work-up. Our findings set the hallmark for
further neuropathological and prospective clinical investigations.
Methods
Study design and study centres. CSF analyses had been planned in Göttingen
before 472 samples were collected from four European centres in the framework of
a retrospective case-control study design. The case selection was based on the
availability of samples from patients with the target conditions (VaD and
important differential diagnoses) and complete information for clinical criteria
application (including basic CSF analyses and neuroimaging). Patients with central
nervous system inflammation and neoplasia (possible causes for white matter
pathology) as well as intermediate diagnostic categories (e.g. possible AD, CJD,
DLB etc.) were excluded. CSF LCN2 analyses (index test) were performed in
Göttingen blind to diagnoses in 2018.
Cohort 1 was recruited at the Clinical Dementia Center and the National
Reference Center for Creutzfeldt-Jakob disease surveillance at the University
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Fig. 5 LCN2 expression in brain tissue and association with glial markers. a LCN2 and GFAP double-immunostaining in the cerebral cortex of control,
AD, and MID cases. LCN2 co-localises with GFAP immunoreactive astrocytes (arrows) in AD, with surrounding plaque like structures, and in MID in
astrocytic scar area (MID-AS). Abundant LCN2+GFAP- cells are observed in MID at the subacute infarction area (MID-SAI; arrow-heads), where there is
little astrocyte presence. Bar= 50 µm. b LCN2 and Iba1 double-immunostaining in the cerebral cortex of control, AD, and MID cases. LCN2 co-localises
with Iba1 immunoreactive microglia in AD and MID-AS (middle panels, arrows). In MID-SAI, predominant Iba1 positive staining was observed, displaying
almost entire colocalisation with LCN2+ cells (bottom panel, arrows). LCN2+Iba1- cells are observed in MID-AS slices (arrow-heads). Bar= 50 µm.
c, d Quantification of (c) LCN2 and GFAP, and (d) LCN2 and Iba1 double-immunostainings. Tables show single- and double-stained area (µm2), percentage
of cells and Pearson’s colocalisation coefficient in Control, AD, and MID (total and divided in MID-SAI and MID-AS). e Graphic representation of double-
stained area (left panel) and percentage of double-stained cells (right panel) in control, AD, MID-SAI, and MID-AS. Data are shown as mean ± SD of
control (n= 4), AD (n= 4), and MID (n= 10). MID-AS areas were quantified in 10 cases and MID-SAI areas in 6 cases. Mean ± SD is included for each
graph. Two-way ANOVA followed by Bonferroni’s post hoc test were used to analyse results *p < 0.05, **p < 0.01, ***p < 0.001.
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-020-14373-2
8 NATURE COMMUNICATIONS |          (2020) 11:619 | https://doi.org/10.1038/s41467-020-14373-2 | www.nature.com/naturecommunications
neurodegenerative dementias as well as patients with VCIND and SVDND. Cohort
2 (ND, AD, and VaD) was recruited at the Dementia Clinic, Neurology
Department of Coimbra-University Hospital (Portugal). Cohort 3 (ND, AD, and
VaD) was recruited at the Geriatric Clinic, Linköping University Hospital,
Linköping (Sweden). Cohort 4 (AD, VaD, VCIND, and SVDND) was recruited at
the Center of Cognitive Neurology and Inserm, Lariboisière Hospital, University
Paris Diderot (France). Case numbers are shown in Table 1.
Diagnostic criteria. The clinical classification of patients and assessment of ima-
ging data was performed in their respective study centres by specialized neurolo-
gists and neuroradiologists. Probable AD was diagnosed according to the National
Institute on Aging—Alzheimer's Association workgroups (NIA-AA) criteria45
(cohort 1,2 and 4) and National Institute of Neurological and Communicative
Disorders and Stroke and the AD and Related Disorders Association (NINCDS-
ADRDA) criteria46 (cohort 3). Patients with coexisting pathology (AD plus VBI)
were excluded from the AD group as much as possible. Only patients without
significant vascular brain lesions (on MRI, rated by the local neuroradiologists) and
no specific clinical signs for cerebrovascular disease (e.g. strokes, stroke-like epi-
sodes, stepwise worsening of symptoms, etc.) were included.
VaD diagnosis in all four centres was based on clinical and radiological criteria
described by the National Institute of Neurological and Communicative Disorders
and Stroke and the AD and Related Disorders Association (NINDS-AIREN2). VaD
diagnosis also included a complete clinical work up showing no evidence for other
than vascular pathology of the brain.
ND patients were diagnosed according to acknowledged standard neurologic
clinical and para-clinical findings based on the International Classification of
Diseases (ICD) 10 definitions. On MRI or CT, these patients did not show any
cerebrovascular lesions other than normal age-related WMH (as rated by
neuroradiologists during the diagnostic process). Neuroimaging and lumbar
puncture were performed for various reasons (e.g. headaches, affective disorders
etc.). ND patients did not show any clinical signs of cognitive impairment but a
detailed neuropsychological test battery had not been performed in many of them.
Data from patients with MD, LBD, FTD, and CJD was only available in cohort
1. The MD group included patients according to clinical International Working
Group (IWG-2) criteria47 and also patients with VaD according to NINDS-AIREN
criteria plus at least one AD-typical CSF biomarker (elevated phosphorylated-tau
or low amyloid beta 1-42/1-40 ratio). The LBD group included dementia with Lewy
bodies48 and Parkinson’s disease dementia49. The FTD group included only
behavioral variant FTD (bvFTD) and was diagnosed according to the International
Behavioral Variant FTD Criteria Consortium for bvFTD50. Patients with Sporadic
Creutzfeldt-Jakob disease (CJD) were classified as probable or definite according to
WHO criteria51.
Classification of cerebrovascular disease. All clinical cohorts included different
forms of VaD while for morphological studies and immunohistochemistry, only
brains with chronic multi-infarct encephalopathy were available.
We analysed clinical and imaging data from all VaD patients to assign disease
type (PSD, SID, and MID) according to the Vascular Impairment of Cognition
Classification Consensus Study8. SID includes cases with severe damage of the
cerebral white matter often accompanied by status cribosus and lacunar infarcts,
MID is characterized by multiple infarcts involving the cerebral cortex but also
other parts of the brain, PSD refers to cases of dementia resulting from a single
stroke.
Cohort 1 and cohort 4 also inlcuded patients with SVDND and VCIND.
Patients with VCIND showed cognitive impairment but no significant impairment
of activities of daily living. Neuropsychological assessment (Cambridge Cognitive
Examination battery in cohort 1 and Consortium to Establish a Registry for AD
battery in cohort 4) did not reveal reduced total or subscale scores in patients with
SVDND (>−1.5 SD, matched for sex, age, and education). The diagnosis of
subcortical small vessel disease was based on MRI (FLAIR or T2 weighted images)
showing ≥4 points on the ARWMC52 scale in cohort 1 and either rank 3 on the
Fazekas scale or multiple lacunae in cohort 4. Patients received MRI for various
reasons (e.g. headaches, affective disorders etc.).
CSF analyses. CSF LCN2 was quantified using the human LCN2/NGAL (Neu-
trophil Gelatinase-Associated Lipocalin) Quantikine Enzyme-linked Immunosor-
bent Assay (ELISA) Kit from R&D according to the manufacturer’s instructions
(R&D Systems, Inc. Minneapolis, MN). CSF samples were diluted 1:2. Inter- and
intra-assay coefficients of variation were below 12 and 10%, respectively. The
limit of quantification was 0.052 (52 pg/ml) and the limit of detection was 0.023
(23 pg/ml). Total-Tau, phospho-Tau (p-Tau), and amyloid beta 42 were quanti-
tatively measured using ELISA kits from Fujirebio (Fujirebio, Ghent, Belgium).
QAlb (CSF albumin/serum albumin*103) was measured by local neurochemistry
laboratories (cohort 1 and cohort 4) according to standard methodology. Test
performers were blind to clinical information and clinical investigators vice versa.
Morphological studies and immunohistochemistry. Morphological studies were
carried out in post mortem human brains obtained from the Institute of Neuro-
pathology brain bank, HUB-ICO-IDIBELL Biobank. One hemisphere was
immediately cut in coronal sections, 1 cm thick. Selected areas of the encephalon
were rapidly dissected, frozen on metal plates over dry ice, placed in individual air-
tight plastic bags, and stored at −80 °C until use for biochemical studies. The other
hemisphere was fixed by immersion in 4% buffered formalin for morphological
studies; sections from representative regions were stained with hematoxylin/eosin,
periodic acid-Schiff and Klüver-Barrera, or processed for immunohistochemistry
analysis. Cases were categorized as controls (cerebral cortex frontal area 8 and
striatum, n= 11), AD (cerebral cortex frontal area 8, AD stage V-VI/C, n= 10),
and MID (cerebral cortex, temporal cortex, striatum, including areas with acute,
subacute, and chronic infarcts, n= 11). Control cases had not suffered from
neurologic or psychiatric diseases, infections of the nervous system, brain neo-
plasms, or systemic and central immune diseases, and did not have abnormalities
in the neuropathological examination. Mixed pathologies were excluded and cases
with circulatory/vascular-linked diffuse white matter encephalopathy and cases
with PSD were not included in the study. CSF was not available in any of the
studied post-mortem brain series.
De-waxed sections, 4-μm thick, were processed for immunohistochemistry. The
sections were boiled in citrate buffer (20 min) to retrieve antigenicity. Endogenous
peroxidases were blocked by incubation in Dako Real Peroxidase blocking solution
(Dako, S2023). Then, sections were incubated at 4 °C overnight with one of the
primary antibodies properly diluted in Dako Real Antibody Diluent (Dako, S2022)
and afterwards incubated with MultiLink biotinylated antibody followed by HRP-
conjugated streptavidin (BioGenex QP9009L-E). The peroxidase reaction was
visualized with diaminobenzidine (DAB; Sigma-Aldrich, D5637) and H2O2.
Control of the immunostaining included omission of the primary antibody.
Nucleus labeling was obtained by Hematoxylin staining. For immunofluorescence,
4-μm-thick de-waxed sections were used. After antigen retrieval, slices were
incubated in Sudan Black for 15 min to reduce lipofuscin autofluorescence.
Unspecific bonding was blocked by Fetal Bovine Serum (FBS) 10% 1h; afterwards
sections were incubated at 4 °C overnight with one of the primary antibodies
properly diluted in FBS 10%. Appropriate Alexa-fluor 488 and 555 were used as
secondary antibodies. Nucleus labeling was performed using DAPI. LCN2 antibody
(RD Systems MAB1757) was used at 1:50 dilution, GFAP antibody (Dako Z0334)
was used at 1:400 dilution, Iba1 antibody (Wako 019-19741) was used at 1:1000
dilution, IgG heavy chain antibody (Proteintech 16402-1-AP) was used at 1:200
dilution, and Fibrinogen FGL2 antibody (Proteintech 11827-1-AP) was used at
1:100 dilution.
LCN2 quantification in brain tissue. Immunohistochemistry and immuno-
fluorescence pictures were taken with a Nikon Eclipse E-800 microscope and
ProgRes Capture Pro 2.7.7 software. LCN2 immunostaining was quantified in 11
controls, 10 AD (stage V-VI/C), and 11 MID cases. Ten images of each slice were
taken throughout the tissue, including areas of subacute and chronic infarcts in
MID slices. Pictures were analysed using Fiji ImageJ software; LCN2 positive area
was measured in µm2 only in particles >25 µm2 by stablishing a fixed positive
staining threshold.
For immunofluorescence, 4 controls, 4 AD, and 10 MID cases were tested. From
MID, six slices were quantified in subacute infarctions (MID-SAI) and 10 in the
astrocytic scar in chronic infarcts (MID-AS). Six pictures of each slice were
analysed using Fiji ImageJ software. Three different methods were applied. The first
one analysed number of green, red and yellow pixel areas using colocalization
thresholded plugin. The second one used Coloc2 plugin to obtain Pearson’s
colocalization coefficients of all pictures. In addition, two independent researchers
counted the number of green, red and yellow cells manually in a double
blind study.
Statistical analysis. Group differences of LCN2 levels were assessed through
linear regression analyses. We log-transformed LCN2 concentration and built
models adjusting for age and sex as potential confounders. Multiple comparisons
among diagnostic groups were made with multcomp package in R53. We per-
formed additional comparisons of LCN2 levels between AD and VaD in the four
cohorts, controlling for dementia stage through models that include age, sex, and
MMSE score as covariates. Models including kidney disease in the group of cov-
ariates were built in order to analyse the potential role of kidney injury as a
confounder of LCN2 levels.
Spearman rank correlation coefficients were used to assess associations between
continuous biomarker levels, ARWMC, and MMSE scores. LCN2 level association
with demographic data was investigated using Pearson correlation (age) or
Mann–Whitney test (sex).
To determine biomarker diagnostic accuracy, ROC curve analyses were carried
out and AUC with 95% CI were calculated. Values of sensitivity and specificity
were derived from best cut-off points in cohort 1 according to Youden’s index.
Comparisons between AUC values were performed with DeLong’s test available in
pROC R package54.
For group comparisons of immunohistochemistry and immunofluorescence
results, Kruskal-Wallis followed by Dunn’s Multiple Comparison test and two way-
ANOVA followed by Bonferroni’s post hoc test were applied respectively, using
GraphPad Prismv5 software. In all analyses, statistical significance was considered
at p < 0.05.
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Ethics. The study was conducted according to the revised Declaration of Helsinki
and Good Clinical Practice guidelines. Informed written consent was obtained
from participants and/or their relatives. The study of CSF samples and case data
was approved by the ethics committees of the University Medical Center Göttingen
(Germany), Linköpping (Sweden), Paris University Hospitals (France), and the
Ethics Board of Coimbra University Hospital (Portugal).
Post mortem brain tissue was obtained from the Institute of Neuropathology
brain bank, HUB-ICO-IDIBELL biobank following the guidelines of Spanish
legislation (Real Decreto de Biobancos 1716/2011).
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
The datasets generated during and/or analysed during the current study contain patient-
related clinical information and are not publicly available. However, anonymised raw
data to generate figures and tables are available from the corresponding authors on
reasonable request.
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